Save time and jump to the most important pieces.
Company | Date | Price Target | Rating | Analyst |
---|---|---|---|---|
11/8/2024 | $90.00 → $137.00 | Neutral → Buy | Goldman | |
10/14/2024 | Mkt Perform → Outperform | William Blair | ||
10/7/2024 | $90.00 → $95.00 | Equal Weight → Overweight | Barclays | |
10/2/2024 | $130.00 → $107.00 | Buy → Neutral | BofA Securities | |
10/1/2024 | $326.00 → $314.00 | Overweight | Morgan Stanley | |
9/24/2024 | $93.00 → $145.00 | Equal-Weight → Overweight | Morgan Stanley | |
9/23/2024 | Buy → Hold | TD Cowen | ||
9/18/2024 | $23.00 → $25.00 | Underweight → Equal Weight | Barclays |
BALTIMORE, Nov. 07, 2024 (GLOBE NEWSWIRE) -- MarketWise, Inc. (NASDAQ:MKTW) ("MarketWise" or "the Company"), a leading multi-brand digital subscription services platform that provides premium financial research, software, education, and tools for self-directed investors, today announced that its Board of Directors declared a quarterly cash dividend to holders of Class A common stock of $0.01 per share on November 1, 2024. A comparable distribution of $0.01 per unit has also been approved to holders of MarketWise, LLC units. The dividend and distribution will be paid on December 26, 2024. The Record Date is November 25, 2024. About MarketWiseFounded with a mission to level the playing fi
Elastic (NYSE:ESTC) ("Elastic"), the Search AI Company, announced that it will release its financial results for its second quarter fiscal 2025 ended October 31, 2024 after the U.S. market close on Thursday, Nov 21, 2024. The company will host a conference call at 2:00 p.m. PT/ 5:00 p.m. ET that day to review its financial results and business outlook. A live webcast of the conference call will be accessible from the Elastic investor relations website at ir.elastic.co. A replay of the webcast will be available for two months. About Elastic Elastic (NYSE:ESTC), the Search AI Company, enables everyone to find the answers they need in real-time using all their data, at scale. Elastic's solu
BALTIMORE, Nov. 07, 2024 (GLOBE NEWSWIRE) -- MarketWise, Inc. (NASDAQ:MKTW) ("MarketWise" or the "Company"), a leading multi-brand digital subscription services platform that provides premium financial research, software, education, and tools for self-directed investors, today reported financial results for third quarter 2024. Third Quarter 2024 Highlights(1) Paid Subscribers were 592 thousand as of September 30, 2024 compared with 774 thousand as of September 30, 2023Total Net Revenue was $97.2 million in third quarter 2024 compared with $106.2 million in third quarter 2023Total Billings was $48.9 million in third quarter 2024 compared with $95.5 million in third quarter 2023Net Inc
4 - Marvell Technology, Inc. (0001835632) (Issuer)
4 - MARKETWISE, INC. (0001805651) (Issuer)
4 - Victoria's Secret & Co. (0001856437) (Issuer)
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Citigroup analyst Paul Lejuez downgraded the rating for Lululemon Athletica Inc. (NASDAQ:LULU) from Buy to Neutral, while cutting the price target from $415 to $300. Lululemon shares settled at $272.06 on Wednesday. See how other analysts view this stock. See how other analysts view this stock. Argus Research analyst Kevin Heal downgraded Zions Bancorporation (NASDAQ:ZION) from Buy to Hold. Zions Bancorp shares closed at $50.98 on Wednesday. See how other analysts view this stock. B
BALTIMORE, Nov. 07, 2024 (GLOBE NEWSWIRE) -- MarketWise, Inc. (NASDAQ:MKTW) ("MarketWise" or "the Company"), a leading multi-brand digital subscription services platform that provides premium financial research, software, education, and tools for self-directed investors, today announced that its Board of Directors declared a quarterly cash dividend to holders of Class A common stock of $0.01 per share on November 1, 2024. A comparable distribution of $0.01 per unit has also been approved to holders of MarketWise, LLC units. The dividend and distribution will be paid on December 26, 2024. The Record Date is November 25, 2024. About MarketWiseFounded with a mission to level the playing fi
Elastic (NYSE:ESTC) ("Elastic"), the Search AI Company, announced that it will release its financial results for its second quarter fiscal 2025 ended October 31, 2024 after the U.S. market close on Thursday, Nov 21, 2024. The company will host a conference call at 2:00 p.m. PT/ 5:00 p.m. ET that day to review its financial results and business outlook. A live webcast of the conference call will be accessible from the Elastic investor relations website at ir.elastic.co. A replay of the webcast will be available for two months. About Elastic Elastic (NYSE:ESTC), the Search AI Company, enables everyone to find the answers they need in real-time using all their data, at scale. Elastic's solu
BALTIMORE, Nov. 07, 2024 (GLOBE NEWSWIRE) -- MarketWise, Inc. (NASDAQ:MKTW) ("MarketWise" or the "Company"), a leading multi-brand digital subscription services platform that provides premium financial research, software, education, and tools for self-directed investors, today reported financial results for third quarter 2024. Third Quarter 2024 Highlights(1) Paid Subscribers were 592 thousand as of September 30, 2024 compared with 774 thousand as of September 30, 2023Total Net Revenue was $97.2 million in third quarter 2024 compared with $106.2 million in third quarter 2023Total Billings was $48.9 million in third quarter 2024 compared with $95.5 million in third quarter 2023Net Inc
8-K - MARKETWISE, INC. (0001805651) (Filer)
10-Q - MARKETWISE, INC. (0001805651) (Filer)
SCHEDULE 13G/A - Elastic N.V. (0001707753) (Subject)
4 - Victoria's Secret & Co. (0001856437) (Issuer)
4 - Marvell Technology, Inc. (0001835632) (Issuer)
4 - Marvell Technology, Inc. (0001835632) (Issuer)
Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. T
Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations Seaport Therapeutics ("Seaport or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. "I am so pleased to welcome Lauren as our CFO as we progress our clinical-stage pipeline of therapeutics for the treatme
MAINZ, Germany, October 31, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")), will host an edition of the Company's Innovation Series R&D Day at 10:30 a.m. Eastern Standard Time (16:30 p.m. CET) on Thursday, November 14, 2024 in New York City, U.S. On the day, BioNTech's leadership team will provide an overview of the Company's corporate strategy and clinical progress across its pipeline. Investors, analysts and the interested public are invited to join the event online via this link. A replay of the webcast will be available shortly after the conclusion of the event and archived on the Company's website for one yea
SC 13G/A - lululemon athletica inc. (0001397187) (Subject)
SC 13G/A - lululemon athletica inc. (0001397187) (Subject)
SC 13G/A - lululemon athletica inc. (0001397187) (Subject)
Goldman upgraded BioNTech from Neutral to Buy and set a new price target of $137.00 from $90.00 previously
William Blair upgraded Elastic from Mkt Perform to Outperform
Barclays upgraded Elastic from Equal Weight to Overweight and set a new price target of $95.00 from $90.00 previously
For Immediate Release: March 26, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: On Monday, the FDA proposed a ban of electrical stimulation devices intended to reduce or stop self-injurious or aggressive behavior, a step rarely taken by the agency. The agency has determined that these devices present an unreasonable and substantial risk of
Submission status for IMMUNOGEN INC's drug ELAHERE (SUPPL-5) with active ingredient MIRVETUXIMAB SORAVTANSINE-GYNX has changed to 'Approval' on 03/22/2024. Application Category: BLA, Application Number: 761310, Application Classification:
Submission status for IMMUNOGEN INC's drug ELAHERE (ORIG-1) with active ingredient MIRVETUXIMAB SORAVTANSINE-GYNX has changed to 'Approval' on 11/14/2022. Application Category: BLA, Application Number: 761310, Application Classification: